Halozyme Therapeutics (HALO) EPS (Diluted) Growth (5y) (2015 - 2026)
Halozyme Therapeutics (HALO) EPS (Diluted) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.42% |
| Dec 31, 2025 | -33.30% |
| Sep 30, 2025 | 41.25% |
| Jun 30, 2025 | 48.06% |
| Mar 31, 2025 | 87.15% |
| Dec 31, 2024 | 45.15% |
| Sep 30, 2024 | 52.14% |
| Jun 30, 2024 | 55.78% |
| Mar 31, 2024 | 117.74% |
| Dec 31, 2023 | 114.09% |
| Sep 30, 2023 | 38.82% |
| Jun 30, 2023 | 40.68% |
| Mar 31, 2023 | 28.42% |
| Dec 31, 2022 | -14.36% |
| Sep 30, 2022 | 87.28% |
| Jun 30, 2022 | 21.93% |
| Mar 31, 2022 | 29.65% |
| Dec 31, 2021 | 32.77% |
| Sep 30, 2021 | 53.55% |
| Jun 30, 2021 | 37.69% |